Cinclus Pharma Holding AB (STO: CINPHA) Stock Analysis & Fundamentals

CINPHACinclus Pharma Holding AB

STO · SE · Healthcare · Drug Manufacturers - Specialty & Generic · cincluspharma.com

13.80SEK+5.34%Mkt Cap: 58.31M $P/E: —Today

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassi…

Industry Peers

Drug Manufacturers - Specialty & Generic

Screen all

MRK

MERCK Kommanditgesellschaft auf Aktien

$65.24BUSDP/E 23.7

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

United Therapeutics Corporation

Swedish Orphan Biovitrum AB

$15.39BUSDP/E 118.0

NBIX

Neurocrine Biosciences, Inc.

Elanco Animal Health Incorporat

Hims & Hers Health, Inc.

Lantheus Holdings Inc

$6.56BUSDP/E 24.0

AMRX

Amneal Pharmaceuticals, Inc.

$6.23BUSDP/E 37.3

INDV

Indivior PLC Ordinary Shares

$4.61BUSDP/E 14.0

HIK

Hikma Pharmaceuticals PLC

$4.32BUSDP/E 12.5

AMLX

Amylyx Pharmaceuticals Inc. Common Stock

Laboratorios Farmaceuticos Rovi, S.A.

$3.34BUSDP/E 16.6

SUPN

Supernus Pharmaceuticals, Inc.

$2.82BUSD

Key Statistics

Company

Market Cap58.31M $

Enterprise Value26.52M $

Revenue (TTM)3.36M $

Gross Profit3.36M $

Net Income (TTM)-17.60M $

Revenue/Share0.0656 USD

Last Price13.80 SEK

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees21

CountrySE

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

ISINSE0020388577

Valuation

P/E (Trailing)—

P/E (Forward)-2.36

PEG—

EV/EBITDA-0.96

EV/Revenue7.88

P/S17.65

P/B3.07

EPS (TTM)-5.33

EPS (Forward)—

52W Range

10.6035% of range19.64

52W High19.64 SEK

52W Low10.60 SEK

Profitability

Gross Margin100.00%

Oper. Margin-5381.14%

EBITDA Margin0.00%

Profit Margin-320.12%

ROE-49.80%

ROA-33.66%

Growth

Revenue Growth-94.80%

Earnings Growth—

Cash Flow & Leverage

Operating CF-7.14M $

CapEx (TTM)108.47K $

FCF Margin-350.43%

FCF Yield-20.22%

Net Debt-31.88M $

Net Debt/EBITDA1.15

Balance Sheet

Debt/Equity0.02

Current Ratio2.30

Quick Ratio2.17

Book Value/Sh4.349 SEK

Cash/Share8.324 SEK

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 SEK

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.0 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)45.25 SEK

Upside (mean)+227.9%

Target Range25.00 SEK – 70.00 SEK

SEK25.00+227.9% to meanSEK70.00

# Analysts4

Ownership

Shares Out.46.54M

Float34.34M

Insiders35.92%

Institutions34.49%

Technical

SMA 5011.78 (+17.2%)

SMA 20015.14 (-8.8%)

Beta—

S&P 52W Chg18.16%

Avg Vol (30d)36.44K

Avg Vol (10d)42.43K

Technical Indicators

RSI (14)64.9

MACD0.0743

MACD Signal0.0298

MACD Hist.+0.0445

BB Upper12.65 SEK

BB Middle12.06 SEK

BB Lower11.46 SEK

BB Width9.90%

ATR (14)0.4890 SEK

Vol Ratio (20d)3.36x